Drs Miller and Burstein discuss advances presented at ASCO 2019 in immunotherapy, CDK4/6 inhibitors, and neoadjuvant TDM-1 therapies for breast cancer. Medscape Oncology
Original Article: Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals